Los Angeles Capital Management LLC Buys 8,920 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX)

Los Angeles Capital Management LLC grew its stake in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) by 39.7% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 31,366 shares of the company’s stock after buying an additional 8,920 shares during the quarter. Los Angeles Capital Management LLC owned 0.05% of Protagonist Therapeutics worth $1,211,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of the stock. RTW Investments LP increased its position in shares of Protagonist Therapeutics by 2.6% in the third quarter. RTW Investments LP now owns 5,426,112 shares of the company’s stock valued at $244,175,000 after acquiring an additional 139,708 shares during the period. State Street Corp increased its position in shares of Protagonist Therapeutics by 52.9% in the third quarter. State Street Corp now owns 3,183,542 shares of the company’s stock valued at $143,259,000 after acquiring an additional 1,101,218 shares during the period. Pacer Advisors Inc. increased its position in shares of Protagonist Therapeutics by 8.2% in the fourth quarter. Pacer Advisors Inc. now owns 1,876,466 shares of the company’s stock valued at $72,432,000 after acquiring an additional 142,376 shares during the period. Geode Capital Management LLC increased its position in shares of Protagonist Therapeutics by 0.3% in the third quarter. Geode Capital Management LLC now owns 1,374,697 shares of the company’s stock valued at $61,873,000 after acquiring an additional 3,528 shares during the period. Finally, Charles Schwab Investment Management Inc. increased its position in shares of Protagonist Therapeutics by 7.6% in the third quarter. Charles Schwab Investment Management Inc. now owns 565,503 shares of the company’s stock valued at $25,448,000 after acquiring an additional 39,850 shares during the period. 98.63% of the stock is owned by institutional investors.

Protagonist Therapeutics Trading Up 3.4 %

Shares of Protagonist Therapeutics stock opened at $37.59 on Friday. The firm has a market capitalization of $2.31 billion, a P/E ratio of 14.13 and a beta of 2.22. The business has a fifty day simple moving average of $37.94 and a two-hundred day simple moving average of $41.81. Protagonist Therapeutics, Inc. has a 12 month low of $24.22 and a 12 month high of $48.89.

Protagonist Therapeutics (NASDAQ:PTGX) last released its earnings results on Friday, February 21st. The company reported $1.98 EPS for the quarter, topping the consensus estimate of ($0.09) by $2.07. Protagonist Therapeutics had a return on equity of 34.68% and a net margin of 52.76%. The business had revenue of $170.64 million for the quarter, compared to the consensus estimate of $56.65 million. Analysts predict that Protagonist Therapeutics, Inc. will post 2.43 earnings per share for the current year.

Wall Street Analysts Forecast Growth

PTGX has been the topic of a number of analyst reports. The Goldman Sachs Group decreased their price objective on shares of Protagonist Therapeutics from $43.00 to $38.00 and set a “neutral” rating on the stock in a research report on Monday, February 24th. Wedbush restated an “outperform” rating and issued a $58.00 price objective on shares of Protagonist Therapeutics in a report on Friday, February 21st. HC Wainwright upped their price objective on shares of Protagonist Therapeutics from $50.00 to $54.00 and gave the stock a “buy” rating in a report on Monday, February 24th. JPMorgan Chase & Co. upped their price objective on shares of Protagonist Therapeutics from $51.00 to $53.00 and gave the stock an “overweight” rating in a report on Tuesday, February 4th. Finally, JMP Securities restated a “market outperform” rating and issued a $58.00 price objective on shares of Protagonist Therapeutics in a report on Friday, February 7th. Two equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Protagonist Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $55.44.

Insiders Place Their Bets

In other news, CEO Dinesh V. Ph D. Patel sold 5,359 shares of the company’s stock in a transaction on Wednesday, February 19th. The stock was sold at an average price of $38.18, for a total transaction of $204,606.62. Following the transaction, the chief executive officer now directly owns 540,260 shares of the company’s stock, valued at $20,627,126.80. This represents a 0.98 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Corporate insiders own 5.40% of the company’s stock.

Protagonist Therapeutics Profile

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.